IDO1 and central nervous system cancer: Recent studies have demonstrated that IL4I1 activates AhR more potently than IDO1 and TDO2 [18], generating indole metabolites and quinolinic acid that promote tumor progression in gliomas and leukemia by enhancing cancer cell motility and suppression immunity.